Effects of benapyrzine, a new antiparkinson drug, on dopamine uptake into corpus striatum.
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology*; D001561:Benzilates / Q000494:pharmacology*; D002395:Catecholamines / Q000378:metabolism; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D004298:Dopamine / Q000378:metabolism*; D005021:Ethylamines / Q000494:pharmacology; D005260:Female; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D007099:Imipramine / Q000494:pharmacology; D066298:In Vitro Techniques; D007700:Kinetics; D009966:Orphenadrine / Q000494:pharmacology; D011437:Propylamines / Q000494:pharmacology; D051381:Rats; D012601:Scopolamine / Q000494:pharmacology; D013574:Synaptosomes / Q000378:metabolism; D014282:Trihexyphenidyl / Q000494:pharmacology; D014316:Tritium
D000978:Antiparkinson Agents; D001561:Benzilates; D002395:Catecholamines; D005021:Ethylamines; D011437:Propylamines; D014316:Tritium; D014282:Trihexyphenidyl; D009966:Orphenadrine; D012601:Scopolamine; D007099:Imipramine; D004298:Dopamine